Nontuberculous Mycobacterial Infection Market
Number of pages: 100 | Report Format: PDF | Published date: March 29, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 12.4 billion |
|
Revenue Forecast in 2031 |
US$ 19.9 billion |
|
CAGR |
5.4% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Class, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global nontuberculous mycobacterial infection market was valued at US$ 12.4 billion in 2022 and is expected to register a revenue CAGR of 5.4% to reach US$ 19.9 billion by 2031.
Nontuberculous Mycobacterial Infection Market Fundamentals
Nontuberculous mycobacteria (NTM) are mycobacteria other than M. leprae and M. tuberculosis, which are the two agents that cause tuberculosis and leprosy. NTM, or environmental, atypical mycobacteria, causes severe infectious diseases in the skin, blood, soft tissues, etc. Despite being common in the environment and routinely isolated from soil or water, NTM is an infrequent human infection. There are around 125 species of mycobacteria, with about 40% potentially being human pathogens. Clinical symptoms, such as pulmonary disease, lymphadenitis, skin and soft tissue infection (SSTI), bone and joint infection, and disseminated infection, are frequently seen in patients, with cervical lymphadenitis being the most typical presentation. Even in children considered immunocompetent, there has been a recent increase in the prevalence and severity of NTM infections. This rise in incidence may be related to the enhanced detection of NTM infections due to faster and more precise laboratory techniques and the increase in the patient population susceptible to NTM infections. Although surgical excision has been the recommended course of action for NTM infections and lymphadenitis, the development of additional macrolides has resulted in significantly more varied therapy options.
[56856]
Nontuberculous Mycobacterial Infection Market Dynamics
The emergence of novel infectious illnesses or the resurgence of old infectious diseases is influenced by various circumstances. While some are the product of human activity, actions are the outcome of natural processes, such as the evolution of viruses over time. Population expansion, migration from rural to urban areas, international air travel, poverty, conflicts, and harmful ecological changes brought on by economic development and land use are some factors that have contributed to these changes in developing nontuberculous mycobacteria infection, which influence the market revenue growth positively.
Concerns over climate change as a contributor to the spread of infectious illnesses are rising. Diseases can travel to new regions when the climate on Earth drastically changes, and habitats change. The rapid spread of antimicrobial resistance is the most crucial factor influencing the development of rare infectious diseases, such as nontuberculous mycobacterium infection. Antimicrobial resistance, or the acquired resistance of infections to antimicrobial drugs such as antibiotics, is a factor that is particularly significant in the resurgence of diseases. Drugs used to treat conditions brought on by infections can become less effective over time due to changes in bacteria, viruses, and other microorganisms. Drugs that were once useful for treating disease are no longer effective. For that reason, there is a huge demand for the alternative treatment of antibiotics for several infectious diseases. The urgent need for alternative drug development is the most crucial factor influencing the fast revenue growth of the global nontuberculous mycobacterial infection market.
A decrease in vaccination rates, wherein an increasing number of people decide not to get vaccinated even when a safe and effective vaccine is available, can also lead to a disease re-emergence. Therefore, a lack of knowledge and awareness about disease prevention also causes a severe outbreak of rare infectious diseases, such as NTM infection. The very young, elderly, pregnant women and those with compromised immune systems are prone to be infected with high-risk factors. Hence, the increasing immunocompromising and the geriatric population are also crucial factors driving the global market revenue growth.
However, strong regulation by governments for new drug development and a lack of proper disease diagnosis are the factors responsible for the hindrance of global nontuberculous mycobacterial infections market revenue growth.
Nontuberculous Mycobacterial Infection Market Ecosystem
The global nontuberculous mycobacterial infection market is analyzed from three perspectives: drug class, distribution channel, and region.
Nontuberculous Mycobacterial Infection Market by Drug Class
[85656]
Based on the drug class, the global nontuberculous mycobacterial infection market is segmented into macrolides, rifampin, aminoglycoside, and others. Further, macrolides are sub-segmented into azithromycin and clarithromycin. The rifampin segment is also sub-segmented into rifabutin and ethambutol. And the aminoglycosides segment is further sub-segmented into streptomycin and amikacin.
The macrolides segment accounted for the largest revenue share of the global nontuberculous mycobacterial infection market in 2022. The mainstays of treatment for MAC lung disease are macrolides (clarithromycin and azithromycin). Macrolides continue to be first-line antibiotics for many infections, notably those caused by intracellular and/or respiratory pathogens, particularly for NTM infections. Despite the paucity of available data, the more recent macrolides, azithromycin and clarithromycin, are also effective in treating orofacial infections. Less gastrointestinal toxicity, higher tissue concentrations, a wider range of gram-negative bacteria, and once- or twice-daily dosing for better patient compliance are their advantages over other classes of antibiotics. In comparison to other antibiotics, macrolide accumulation in inflammatory cells and delivery to the site of the infection are noteworthy advantages.
Significant medication interactions are linked to erythromycin and clarithromycin. Furthermore, it has been shown that macrolide maintenance therapy effectively lowers the inflammation caused by NTM infection. This is probably because macrolide maintenance therapy also has a direct antibacterial impact in addition to an anti-inflammatory effect.
Nontuberculous Mycobacterial Infection Market by Distribution Channel
Based on the distribution channel, the global nontuberculous mycobacterial infection market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies segment accounted for the largest revenue share of the global nontuberculous mycobacterial infection market in 2022. Hospital pharmacies also supervise drug interactions, educate patients and healthcare professionals on medication usage, and establish quality control plans to guarantee the safe and effective usage of drugs. Hospital pharmacies significantly impact the financial aspects of healthcare expenses. Moreover, they provide patients with appropriate medication instructions and counseling to ensure the safe and effective administration of pharmaceuticals, which can ultimately result in cost savings for the healthcare system. In addition, pharmacists can help identify drug interactions or negative effects, which can help improve patient outcomes and save healthcare costs.
Various government programs, including the subsidized medicine program, assist patients in purchasing pricey therapies for uncommon ailments regardless of their financial conditions. Due to rising prescription costs and the dearth of pharmaceuticals in retail pharmacies, people now prefer hospital pharmacies, which has significantly increased revenue. Additionally, hospital pharmacies have expanded their services by providing home delivery of medications and pharmacist consultations to make it easier for patients to receive their drugs. This has additionally helped hospital pharmacists earn a prominent market revenue share.
Nontuberculous Mycobacterial Infection Market by Region
Based on the region, the global nontuberculous mycobacterial infection market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounted for the largest revenue share of the global nontuberculous mycobacterial infection market in 2022. The expansion of key companies and their coordinated efforts to create novel formulations and guarantee high-quality products are also anticipated to increase regional segment revenue growth. A significant revenue growth factor for the therapeutic system is the rising prevalence of NTM infection in the region. In the United States, estimates for the annual prevalence of pulmonary NTM illness range from 1.4 to 13.9 per 100,000 people. Also, according to the American Lung Association, in the United States, there are probably more than 86,000 persons who have NTM infectious lung disease. Rates seem to be rising, especially in older adults and women. The major market participants have introduced cutting-edge drugs to treat infectious diseases, thereby boosting their revenue share. The government has taken steps to provide citizens with cutting-edge facilities for the treatment of infectious diseases. A significant possibility for market expansion is the enormous population of individuals in the high-income category. The increase in the average person’s disposable income has also become a significant potential. People with high disposable incomes can choose to receive cutting-edge medical care, which supports market expansion.
Nontuberculous Mycobacterial Infection Market Competitive Landscape
The global nontuberculous mycobacterial infection market appears to have a moderate level of competition, potentially influenced by various factors such as new product launches, mergers, and acquisitions. Some of the primary development strategies that many organizations are prioritizing include the introduction of novel therapies, securing approval for those goods, and taking part in additional initiatives, including awareness projects. Moreover, partnerships, acquisitions, and numerous other forms of collaborations are identified in the market as potential revenue growth strategies. With the expanding global market demand for effective drugs to treat NTM infections, these actions have raised the prospect of having profitable revenue growth prospects in the future.
Notable market participants include:
Nontuberculous Mycobacterial Infection Market Strategic Developments
Nontuberculous mycobacteria (NTM), also known as mycobacteria other than tuberculosis, or atypical mycobacterium, is an environmental mycobacterium that is all-pervasive and concentrated in soil and water. It causes cough, fatigue, weight loss, night sweats, occasionally dyspnea and hemoptysis, and NTM lung disorders in severe cases.
The increasing prevalence of infectious diseases and the rising need for better treatment options fuel the revenue growth of the global nontuberculous mycobacterial infection market.
Rising antimicrobial resistance owing to the complexities in treatment is the most important restraining factor for the revenue growth of the global NTM infection market.
Key companies operating the global nontuberculous mycobacterial infection market are Novartis AG, GlaxoSmithKline plc, SUN PHARMACEUTICAL INDUSTRIES LTD., F. Hoffman La Roche AG, and Peptron Inc.
The global nontuberculous mycobacterial infection market is expected to register growth at a revenue CAGR of 5.4% during the forecast period from 2023 to 2031.
*Insights on financial performance are subject to the availability of information in the public domain